Drug profile

The FDA adverse-event record for Clostridium Chauvoei Bacterin Toxoid + Clostridium Novyi Bacterin Toxoid + Clostridium Perfringens Type C Bacterin Toxoid + Clostridium Perfringens Type D Bacterin Toxoid + Clostridium Septicum Bacterin Toxoid + Clostridium Sordellii Bacterin Toxoid + Moraxella Bovis Bacterin Toxoid

26 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Clostridium Chauvoei Bacterin Toxoid + Clostridium Novyi Bacterin Toxoid + Clostridium Perfringens Type C Bacterin Toxoid + Clostridium Perfringens Type D Bacterin Toxoid + Clostridium Septicum Bacterin Toxoid + Clostridium Sordellii Bacterin Toxoid + Moraxella Bovis Bacterin Toxoid. See the species affected, top reactions, and outcomes below.

26
adverse-event reports
42.3%
death-coded share
Cattle
most-reported species
11
Lack of efficacy - NOS - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
26
Total Reports
11
Deaths Reported
42.3%
Death Rate

Active Ingredients

Clostridium Chauvoei Bacterin ToxoidClostridium Novyi Bacterin ToxoidClostridium Perfringens Type C Bacterin ToxoidClostridium Perfringens Type D Bacterin ToxoidClostridium Septicum Bacterin ToxoidClostridium Sordellii Bacterin ToxoidMoraxella Bovis Bacterin Toxoid

Administration Routes

UnknownSubcutaneous

Species Affected

Cattle 26

Most Affected Breeds

Cattle (other) 17
Aberdeen Angus 5
Crossbred Bovine/Cattle 2
Cattle (unknown) 2

Most Reported Reactions

Lack of efficacy - NOS 11
Death 10
Lack of efficacy (bacteria) - NOS 7
CULTURE/TITER DATA ABNORMAL 3
PR-LIVER, LESION(S) 2
Respiratory signs 1
INEFFECTIVE, ANTIBIOTIC 1
Tachypnoea 1
Fever 1
Anorexia 1
Lung sound 1
Laboured breathing 1

Outcome Breakdown

Outcome Unknown
15 (36.6%)
Died
11 (26.8%)
Recovered/Normal
8 (19.5%)
Ongoing
4 (9.8%)
Recovered with Sequela
3 (7.3%)

Clostridium Chauvoei Bacterin Toxoid + Clostridium Novyi Bacterin Toxoid + Clostridium Perfringens Type C Bacterin Toxoid + Clostridium Perfringens Type D Bacterin Toxoid + Clostridium Septicum Bacterin Toxoid + Clostridium Sordellii Bacterin Toxoid + Moraxella Bovis Bacterin Toxoid Adverse Event Insights

26 reports name Clostridium Chauvoei Bacterin Toxoid + Clostridium Novyi Bacterin Toxoid + Clostridium Perfringens Type C Bacterin Toxoid + Clostridium Perfringens Type D Bacterin Toxoid + Clostridium Septicum Bacterin Toxoid + Clostridium Sordellii Bacterin Toxoid + Moraxella Bovis Bacterin Toxoid; 11 recorded a death outcome (42.3% of reported events, not a population-level mortality rate). Active ingredients: Clostridium Chauvoei Bacterin Toxoid, Clostridium Novyi Bacterin Toxoid, Clostridium Perfringens Type C Bacterin Toxoid, Clostridium Perfringens Type D Bacterin Toxoid, Clostridium Septicum Bacterin Toxoid. Administration routes: Unknown, Subcutaneous.

By species: Cattle (26 reports). By breed: Cattle (other) (17), Aberdeen Angus (5), Crossbred Bovine/Cattle (2).

Leading clinical signs: Lack of efficacy - NOS (11), Death (10), Lack of efficacy (bacteria) - NOS (7), CULTURE/TITER DATA ABNORMAL (3). Outcome, 41 coded reports: Outcome Unknown leads at 36.6%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.